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Drug Matrix cell C1: Management/supervision: Reducing harm
S  Forced discharge and drop-out mean more post-methadone deaths  (1999). Ci tes  US study (1998) which found that in the fi rst
year after leaving a  methadone programme the death rate was  eight times higher than among patients  who remained in treatment;
al l  nine deaths  were of patients  who had dropped out or been discharged for breaking programme rules , and two-thirds  were
overdoses. For related discuss ions  cl ick here and here and scrol l  down to highl ighted headings.
K  Slow ‘cascade’ of anti -overdose training from staff to other staff and patients  (2011). Drug service staff in England trained in
overdose recovery us ing naloxone then trained other staff and patients , but why on average did each cl inician train just one drug
user every 11 months? From same study report on resulting use of naloxone (2008) and a fol low-up (2009) of some of the trainees
which revealed reluctance to carry around naloxone ki ts , partly due to having completed treatment intended to divorce them from
drug use and by extens ion, drug us ing associates . For discuss ion cl ick here and scrol l  down to highl ighted heading.
K  Prematurely discharging heroin users  from treatment risks  l ives  (2007). Reports  on a large Ita l ian study which demonstrated the
protection against overdose deaths  afforded by being in treatment, and the danger of leaving with reduced tolerance to opiate
drugs  but sti l l  vulnerable to relapse. For managers , highl ights  the di lemma of balancing retention with throughput, and enforcing
expectations  and rules  with keeping ‘problem’ patients  safe(r). For discuss ion cl ick here and scrol l  down to highl ighted heading.
K  Supervised consumption cuts  methadone deaths  (2010). From the mid 1990s  Bri tish addiction treatment cl inics  started to
require patients  to take their methadone under medical  supervis ion, preventing divers ion to the i l l i ci t market and thousands of
overdose deaths.
K  Di lemma posed by continued i l legal  drug use during methadone treatment (2013). In Norway even patients  in the top quarter for
continuing drug use whi le on methadone benefi ted from a near four-fold reduction in the number of courses  of hospital  treatment
needed for drug-related phys ical  complaints . These episodes  rebounded when patients  were forced to or chose to leave. Simi lar
findings  have come from Sweden (2009), where during an enforced gap in treatment for breaking programme rules  (usual ly by
continuing to use i l legal  drugs), hospital  admiss ions  rose only to fa l l  again when the same addicts  were al lowed to return. For
related discuss ions  cl ick here and here and scrol l  down to highl ighted headings.
K  Vancouver’s  needle exchange: lessons  of fa i lure (2012). The ci ty which hosted North America’s  most prol i fic exchange
nevertheless  saw HIV and hepati tis  C sweeping through i ts  drugs  quarter. Prime among the reasons  are bel ieved to have been
restrictions  imposed and sel f-imposed on the service, including l imited opening hours  and one-for-one exchange. Related review
below. For discuss ion cl ick here and scrol l  down to highl ighted heading.
R  Don’t restrict supply of injecting equipment (2013). Extens ive UK review updated in 2013 which underpinned NICE guidance 
below. The reviewers  found cons istent evidence that more l iberal  supply of injecting equipment was  associated with less  risky
injecting practices . For related discuss ion cl ick here and scrol l  down to highl ighted heading.
R  Chal lenge of reconci l ing community concerns  with needle exchange priori ties  (2003 and 2004). Four-part series  from Drug and
Alcohol  Findings  highl ights  the chal lenge of freely distributing the “flood” of injecting equipment needed to curtai l  hepati tis  C and
managing local  wariness  about needle exchange fuel led particularly by discarded syringes. Part 2 includes  the instructive case
study of Vancouver, subject of key study above. For discuss ion cl ick here and scrol l  down to highl ighted heading.
G  NICE says  abundance is  the objective for injecting equipment provis ion ([UK] National  Insti tute for Health and Care Excel lence,
2014). UK’s  health technology regulator says  exchange service managers  should a im for every injector to have more steri le
injecting equipment than they need for every injection. Also avai lable NICE-endorsed checkl ist to audit compl iance (2015) with
recommendations. For discuss ion cl ick here and scrol l  down to highl ighted heading.
G  Scottish guidance on running and commiss ioning needle exchanges  (Scottish Government, 2010). Includes  needs assessment,
locations, opening hours , s taff tra ining, injecting equipment provis ion pol icies , and integration with other services . Cal ls  on
services  to redress  the large shortfal l  in supplying enough needles/syringes  for each injection.
G  WHO guide to starting and managing needle and syringe programmes (World Health Organization [etc], 2007). Rare in this
sector to have what is  effectively a  management manual , a  s ign of the importance WHO attaches  to making needle exchanges  as
effective as  poss ible to combat HIV. Also issued by a  UN agency is  a  s imi lar guide (United Nations  Office on Drugs  and Crime, 2014)
for prisons  and other closed settings . For discuss ion cl ick here and scrol l  down to highl ighted heading.
G  UN guide on planning, coordinating and managing comprehensive HIV and hepati tis  C programmes for injectors  (United Nations
Office on Drugs  and Crime, 2017). Includes  guidance on needle exchange, substi tute prescribing, treatment of infection, naloxone
distribution, education, and address ing risk of sexual  transmiss ion.
G  How UK treatment services  can help reduce drug-related deaths  (Col lective Voice and NHS Substance Misuse Provider Al l iance,
2017). Recommendations  and practice examples  developed (with the support of Publ ic Health England) by bodies  representing drug
and alcohol  services  in England.
G  Scottish Drugs  Forum naloxone web s i te. Offers  resources, advice, guidance, information and news on programmes featuring the
drug naloxone which reverses  opiate overdose. Being reconstructed at time of writing.
G  EU advice on preventing overdose through naloxone programmes (European Monitoring Centre for Drugs  and Drug Addiction
[EMCDDA ], 2016). Background information on naloxone and in chapter 5 advice on setting up take-home naloxone training and
distribution programmes.
G  Balancing recovery ambition with safety and harm reduction ([UK] National  Treatment Agency for Substance Misuse, 2012).
Cl inical  consensus  developed for UK government on how drug-based treatment for heroin addiction can be made more recovery-
oriented without los ing harm reduction benefi ts . See also supplement (2013) on reviewing patients  to see i f treatment should be
changed or ended. For discuss ion cl ick here and scrol l  down to highl ighted heading.
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What is this cell about? As described more fully in cell A1’s bite, about reducing the harms experienced
by the user as a result of their drug use, without necessarily reducing use or seeking to overcome dependence.
Common interventions include needle exchanges, overdose prevention programmes, and substituting a legally
prescribed drug of the same type for the original (and usually illegally obtained) substance, also considered as
a treatment for addiction in row 3 of the matrix. This cell is not about the effectiveness of the intervention
itself (for which see cell A1), but how implementation and effectiveness are influenced by the management
functions of selecting, training and managing staff, and managing the intervention programme – less
commonly researched topics.
Where should I start? If you find yourself having to manage a needle exchange (or establish one from
scratch), it would be hard to find a better starting point than the World Health Organization’s guide on how to
maximise your programme’s anti-infection potential. That such a guide should be produced (along with
another on exchange in prison) is a sign of the importance WHO attaches to making needle exchanges
effective, and in particular, increasing their coverage – the degree to which sterile equipment is in practice
available in sufficient numbers to be used for every injection. In the UK and elsewhere, adequate coverage
recognised as the key to the success of needle and syringe programmes.
WHO’s guide seems to cover just about everything you need to run an exchange, in a text characterised by a
determination to work out in detail what commitment to the human rights of injectors and to public health
means for the nuts and bolts of needle exchange provision. Another strength is its awareness of what
exchanges must fit their services around – the reality of life for injectors – yet also of the need for pragmatism
and ‘politics’ in responding to community concerns and authorities like the police, who can make or break
exchange provision. An example is found on page 19, where the guide explains why insisting on one-for-one
exchange is bound to lead to some avoidable sharing of equipment, yet recognises that services may need to
start up this way where there is needle and syringe provision is seen as controversial or undesirable.
A broader guide to planning and implementing anti-infection policies and services has also been produced by
WHO and other agencies of the United Nations. It includes needle exchange alongside other measures,
showing what a comprehensive national programme would look like. The emphasis is more on planning and
establishing services than day-to-day management, but managers will still find important principles and
guidance.
Highlighted study The risks for opioid users of fatal overdose after leaving (or being forced to leave)
treatment were comprehensively and graphically demonstrated in the large-scale Italian VEdeTTE study, in the
process highlighting the life-and-death dilemmas faced by managers in determining treatment exit policies.
Leaving methadone treatment and the post-discharge period after completing residential detoxification were
already established as times of heightened risk. VEdeTTE went further, documenting the risk of leaving any
treatment among 10,454 heroin users who had started treatment in 1998–2001 at about a quarter of Italy’s
national health service treatment centres. Unlike similar UK studies, it did not rely entirely on routinely
collected statistics, but gathered data directly from the patients, enabling it to adjust for pre-existing risk
factors. Apart from the therapeutic communities, nearly all the treatments were conducted on an outpatient
basis.
The results showed that the risks of leaving treatment were more general than previously appreciated. Across
the whole sample, for an equivalent number of people over an equivalent time, overdose deaths after leaving
were 11 times more frequent than during treatment. Narrowing in on the month after leaving, the rate was 27
times higher.
VEdeTTE showed that the post-detoxification risk extended to outpatient as well as inpatient programmes;
leaving outpatient detoxification was associated with an overdose death rate over nine times greater than
during treatment overall. Deaths were concentrated among the detoxification ‘successes’. Patients who had
completed outpatient methadone-based detoxification were four times as likely to die from overdose as those
who had failed to complete; six of the seven deceased were detoxification completers, just one a drop-out.
Worst of all was the overdose death rate after leaving residential therapeutic communities – 23 times the rate
during treatment overall, a striking contrast to zero deaths while protected by the residential environment. All
nine post-rehabilitation deaths were among people who had dropped out of the centres.
Our analysis focused on overdose deaths after detoxification and residential rehabilitation, but the death rate
also rose by over seven times from before to after exiting methadone maintenance programmes, leaving the
former patients over eight times more likely to fatally overdose than during treatment overall. All but one of
the five deaths were among programme drop-outs.
Of particular interest for the formulation of treatment-exit policies were the differences in who was most at
risk after leaving: drop-outs from residential rehabilitation and methadone maintenance, but in outpatient
detoxification, the people who did not drop out and instead completed the programme.
Though the numbers were too small to be sure, VEdeTTE’s analysts also calculated that the balance between
the protection associated with being in treatment versus the steeply increased risk of fatal overdose in the
month after leaving, meant that short periods in treatment were likely to be associated with more overdose
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month after leaving, meant that short periods in treatment were likely to be associated with more overdose
deaths than no treatment.
Reinforced by other studies including some from the UK, VEdeTTE’s results seems to emphasise the
importance of creating no unnecessary barriers to patients completing rehabilitation and of making involuntary
discharge a rare last resort, of retaining patients in methadone maintenance even if they do not fully comply
with treatment and continue to use illegal drugs, and of post-treatment support and/or follow-on treatment to
prevent deaths due to resumption of opioid use after losing tolerance to the drugs.
Treatment exit through drug-free discharge is considered a marker of successful treatment, but it seems
‘success’ can sometimes carry a much higher risk of death than ‘failure’. The implication is that concern in the
name of ‘recovery’ to increase drug-free treatment completions and to meet patients’ ambitions to stop taking
opiate-type drugs, must be tempered by awareness of the risks. The challenge posed for managers of
treatment services is the subject of the next section.
Issues to consider and discuss
 Does staying safe(r) mean staying? If you have not already absorbed these, look back at the findings
of the Italian VEdeTTE study described in the Highlighted study section. They bring home the challenge to
managers of setting criteria and procedures for the possibly life-and-death decision on terminating treatment,
and of establishing programmes patients want to stay in, which as a far as possible avoid terminating
treatment, yet productively challenge patients and enforce limits required for a safe and therapeutic
environment.
In one way that challenge is at its height when there is no ‘natural’ end to treatment, as in methadone
maintenance and allied treatments, which substitute a safer, legal and less disruptive opioid drug for the one
the patient has become dependent on. As normally implemented, these treatments act like a light switch:
rapid remission in illegal heroin use when switched on, rapid and life-threatening relapse on departure. The
evidence has been there for decades and is particularly strong from Scandinavia: for a brief account unfold 
the supplementary text.
This was one of the issues faced by a government-initiated expert review of methadone and allied treatments
in England, and faced again when via the Chief Medical Officer, government asked the experts to look again at
how and when clinicians should review continuation of a patient’s treatment.
Published in 2013, the expert group’s response extracted the therapeutic positives from this challenge in the
form of a renewed emphasis on patients progressing in treatment towards more satisfactory lives – meaning
more could stop drug use and leave treatment sooner – while rejecting extensions to this ambition which pose
moving out of treatment as a must-do step towards what has been labelled “full” recovery. Neither leaving
treatment in general, nor withdrawing from prescribing-based treatments in particular, are seen in the report
as essential to recovery: for more about the group’s conclusions unfold  the supplementary text.
The group’s thinking fed into the broader clinical guidelines developed by experts in the field and published in
2017 by UK national governments. They stress the importance of aftercare planning, including scheduled
‘recovery check-ups’, and provision for rapid re-engagement in treatment of former patients at risk of relapse.
A degree of continued drug use is not in itself seen as a reason for declaring treatment a failure and, by
extension, also not in itself a reason for terminating that treatment, which may need in some cases to be
lifelong. But they acknowledge that involuntary discharge can be justified if a patient if is not benefiting from
treatment: “Any response should be based on the assessment of relative risks to the patient and staff, while
maintaining the integrity of the treatment programme … A decision to temporarily or permanently exclude a
patient from a drug treatment service or provide coerced detoxification should not be taken lightly. Such a
course of action can put the patient at an increased risk of overdose death, contracting a blood-borne virus or
offending.”
What amounts to a professional obligation is placed by the guidelines on clinicians, commissioners and
service providers to make non-agreed termination of treatment very much the exception, and a decision taken
under the weight of the knowledge that it could place the patient – and their associates and the wider
community – at greater risk.
Take a look at the conclusions of the expert group on reviewing, adjusting and terminating maintenance
treatment, and the stance taken in the clinical guidelines on similar issues in section 4.6 starting page 104.
Are they clear enough, should they have been more explicit about when and when not to terminate, or is this
best left to each treatment service’s policies and the judgement of patients and clinicians? Bear in mind that
(as seems likely to be increasingly the case) when treatment slots are too few to meet demand, each patient
retained in treatment on the grounds that they are partially benefiting or at least not deteriorating, blocks a
slot for another patient who might benefit more. Yet as a patient, you may feel you have the right to have your
welfare placed centre stage by your treatment service, rather than weighed in the balance with that of
potential patients.
 Are the days of needle ‘exchange’ behind us? ‘Exchange’ used to be a distinctive and essential
element of needle exchange services – that new sterile injecting equipment would be supplied (more or less
strictly) in return for used equipment, taking these potential disease carriers out of circulation and keeping the
streets clear enough of needles and syringes to defuse opposition to ‘colluding’ with illegal drug use and
attracting ‘junkies’ to the neighbourhood. In the early days of needle exchange, the ‘return rate’ was a key
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In the early days of needle
exchange, the ‘return rate’
was a key statistic – a badge
of respectability
How do you maintain
optimism without this
seeming to be flatly
contradicted by issuing
naloxone kits?
attracting ‘junkies’ to the neighbourhood. In the early days of needle exchange, the ‘return rate’ was a key
statistic – a badge of respectability.
From the fieldwork conducted for NICE in preparation for their
recommendations on needle exchange, it seems these days this
former priority mainly lingers on only as an unenforced ambition,
honoured almost entirely in the breach. “Unrestricted distribution”
is now the norm, and insisting on return of used equipment before
new equipment is supplied is seen as a barrier to ensuring every
injector has more than enough equipment to inject safely every time, needed to appreciably intercept
transmission of hepatitis C. Instead of returning used equipment to exchanges, ‘drop boxes’ or safe bins where
injectors can dispose of their equipment have gained greater prominence.
For confirmation of how needle exchange can be undermined by restrictive exchange (and other) polices, look
at one of our key studies. It explains why despite Vancouver hosting what was then North America’s most
prolific needle exchange, nevertheless HIV and hepatitis C swept through the Canadian city’s drugs quarter.
Vancouver was also a case-study city in Part 2 of a series by Drug and Alcohol Findings on needle exchange
and hepatitis C. The important of the city’s experience can hardly be overestimated – though more as a lesson
in what not do than as an exemplar.
In Britain, do any of the original reasons for the exchange policy still hold to any degree? According to the
research report on the pilot exchange schemes, the rationale was:
• To stop used and possibly infected needles being left in public and other places, or otherwise disposed of in
a way that may be hazardous to others.
• Exchanging syringes makes it less likely that syringes will be circulated and reused.
• Making the client return to the agency frequently increases the opportunity for advice and counselling.
• Needle exchange schemes would find it difficult to operate if there were substantial complaints from the
public about discarded syringes.
 The challenge of planning for relapse in a recovery-oriented treatment service Naloxone
rapidly reverses the effects of opiate-type drugs, including the respiratory depression which causes overdose.
It became the main new hope for curbing the death rate after in 2005 UK law was amended to permit
emergency administration by any member of the public. As a technique, administering naloxone seems close
to a sure-fire solution to this top cause of sudden death among drug users, but as often the case,
implementation rather than efficacy is the weak link.
Obstacles to effective distribution are many. Among them is a contradiction between the optimistic prospect
of recovery from addiction, and preparing for this ambition to crash in the form of life-threatening relapse. For
treatment services, acknowledging the likelihood that their patients will relapse may be a hard pill to swallow,
and catering for this by training clients and families to administer naloxone may seem to counter-
therapeutically undermine the optimism at the heart of the recovery movement. Similarly, for patients looking
forward to a new life where they have escaped drugs and drugtaking circles, learning a lifesaving technique
predicated on continued drug use and/or continued contact with drug users may feel undermining and
irrelevant, one reason why issued naloxone kits sometimes get unused.
These sensitivities may mean that the times when opiate users are most vulnerable to overdose – after
successfully ‘graduating’ from treatment having achieved abstinence – are also the times when they and their
families are least receptive to anti-overdose training.
Going back several decades, treatment and rehabilitation services,
including those which today would be called recovery-oriented,
found ways of accommodating similar apparent contradictions
when it became important to counsel drug users leaving treatment
about the risks of HIV transmission, effectively acknowledging the
possibility of relapse to injecting drug use. How in the ‘recovery’
era will this new challenge of accommodating to the possibility –
even the likelihood – of relapse play out? How as a manager do you guide your staff in unshakably maintaining
optimism for their patients and clients, without this seeming to be flatly contradicted by issuing them with
naloxone kits and conducting related training?
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